First variants of the Klebsiella pneumoniae carbapenemase (KPC), KPC-2 and KPC-3, have
encountered a worldwide success, particularly in K. pneumoniae isolates. These beta …

The treatment of multidrug-resistant Gram-negative bacteria (MDR-GNB) infections in
critically ill patients presents many challenges. Since an effective treatment should be …

Understanding the nuances of AmpC β-lactamase–mediated resistance can be challenging,
even for the infectious diseases specialist. AmpC resistance can be classified into 3 …

The comparative efficacy of ceftazidime-avibactam and meropenem-vaborbactam for
treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections remains unknown …

The management of carbapenem-resistant infections is often based on polymyxins,
tigecycline, aminoglycosides and their combinations. However, in a recent systematic …

ABSTRACT Ceftazidime/avibactam (CAZ-AVI), approved in 2015, is an important first-line
option for KPC-producing Enterobacterales (KPC-E). Although still uncommon, resistance to …

Carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP), a type of Klebsiella
pneumoniae (KP) that exhibits hypervirulence and carbapenem resistance phenotypes, can …

Microbial resistance is a serious threat to human health worldwide. Among the World Health
Organisation's list of priority resistant bacteria, three are listed as critical—the highest level of …

ABSTRACT Introduction: Antimicrobial resistance in Gram-negative pathogens is a
significant threat to global health. β-Lactams (BL) are one of the safest and most-prescribed …

Multidrug-resistant (MDR) Klebsiella pneumoniae represents an increasing threat to human
health, causing difficult-to-treat infections with a high mortality rate. Since colistin is one of …